Giant cell tumor of bone following denosumab treatment: assessment of tumor response using various imaging modalities

ConclusionBased on the ICDS criteria, most patients with giant cell tumor of bone show objective tumor response to denosumab. Modification of ICDS to include marginal sclerosis or clear demarcation of the lesions might be considered as a separate response criterion to accurately assess the treatment response in patients with GCT.

Source: Insights into Imaging - February 26, 2020 Category: Radiology Source Type: research